Equine gastric disease treatment grows more lesion-specific

Equine gastric disease remains common in practice, but the treatment conversation is getting more precise. A recent educational piece from The Horse highlights the core clinical approach: confirm the diagnosis, use pharmacologic therapy appropriately, and pair it with management changes. That message aligns with the broader literature, which increasingly separates equine squamous gastric disease from equine glandular gastric disease rather than treating both as a single “ulcer” problem. (extension.usu.edu)

That distinction matters because the two syndromes do not behave the same way. ESGD is closely linked to acid exposure in the squamous mucosa and generally responds well to proton pump inhibition. EGGD appears more complex, with inflammation, erosions, and risk factors that may include exercise intensity, management stressors, diet, and NSAID exposure. Reviews and primary studies have also emphasized that clinical signs alone are unreliable, making gastroscopy the key tool for diagnosis and follow-up. (pubmed.ncbi.nlm.nih.gov)

On the pharmacology side, omeprazole remains the backbone of treatment, especially for ESGD. Evidence summarized in reviews and meta-analysis shows omeprazole prophylaxis can significantly reduce ulcer occurrence in actively training horses, and historical safety and efficacy studies support 28-day treatment courses for healing and lower-dose continuation strategies to reduce recurrence risk. Additional options discussed across veterinary sources include sucralfate, H2-receptor antagonists such as ranitidine and famotidine, and misoprostol, particularly when glandular disease or NSAID-associated injury is part of the picture. (pubmed.ncbi.nlm.nih.gov)

But the newer literature also shows the limits of a one-size-fits-all approach. In a clinical study indexed in PubMed, misoprostol outperformed combined omeprazole-sucralfate for healing and improving EGGD lesions, adding to the case for lesion-specific treatment decisions. Other work suggests diet composition can influence glandular disease outcomes, and transportation, fasting, and training-related management may contribute to lesion development or worsening. In other words, medication still matters, but so does the environment the horse returns to after treatment. (pubmed.ncbi.nlm.nih.gov)

Industry interest in nonpharmaceutical support remains high, but the latest evidence is mixed. A 2026 PubMed-listed trial of a nutraceutical containing lecithin, pectin, and meadowsweet, given after omeprazole treatment, did not significantly reduce recurrence of ESGD or EGGD compared with placebo when horses were reassessed by gastroscopy. The authors did report shifts in salivary biomarkers that may point to effects on mucosal health, but the main clinical endpoint did not move. That’s an important signal for veterinarians and pet parents alike: promising biologic markers are not the same as demonstrated prevention of lesion recurrence. (pubmed.ncbi.nlm.nih.gov)

Why it matters: For equine practitioners, this is a reminder to avoid collapsing all gastric disease into a single treatment pathway. Horses with suspected gastric disease still need a definitive diagnosis when possible, lesion mapping matters, and follow-up gastroscopy may be more informative than reported symptom improvement alone. It also reinforces the need to counsel pet parents on management, including forage access, feeding patterns, travel, training stress, and NSAID use, because recurrence risk remains high once medication stops. (pubmed.ncbi.nlm.nih.gov)

What to watch: The next phase of this story is likely to center on better recurrence-prevention strategies, more targeted protocols for EGGD, and stronger evidence on where nutraceuticals fit, if at all, alongside proven pharmacologic therapy and management change. (pubmed.ncbi.nlm.nih.gov)